Recent progress in vaccine development targeting pre-clinical human toxoplasmosis

Area of Science:

• Veterinary immunology
• Parasitology
• Vaccine development

Background:

• Toxoplasma gondii is an intracellular parasite affecting all warm-blooded vertebrates.
• There is currently no commercially available vaccine for human toxoplasmosis.
• Preclinical research is actively investigating various vaccine candidates.

Purpose of the Study:

• To review the progress in Toxoplasma gondii vaccine development.
• To analyze findings from preclinical studies using DNA, protein subunit, and virus-like particle platforms.
• To provide insights into rational vaccine design for toxoplasmosis.

Main Methods:

• Literature review of preclinical Toxoplasma gondii vaccine studies.
• Focus on studies involving challenge infection in mice.
• Analysis of vaccine platforms including DNA, protein subunit, and virus-like particles.
• Inclusion of studies published within the last 5 years.

Main Results:

• Preclinical vaccines expressing diverse antigens show protective efficacy in animal models.
• Antigen selection and immunization strategies are crucial for enhancing protection.
• While current vaccines do not eliminate tissue parasites, they demonstrate developmental potential.

Conclusions:

• Progress in DNA, protein subunit, and virus-like particle vaccine platforms offers hope for future toxoplasmosis vaccines.
• Further research is needed to optimize vaccine design and achieve complete parasite clearance.
• Preclinical findings guide rational vaccine design for controlling toxoplasmosis.